Funding Received
$3.8 Million in 2 Rounds from 2 Investors
Most Recent Funding
$2.1 Million Series B on June 18, 2013
Founded:
2009
Headquarters:
Zürich
Description:
InSphero is a leading supplier of organotypic, biological, in vitro 3D microtissues for highly predictive drug testing.
Categories:
Biotechnology
Website:
http://www.insphero.com

Detailed Description

Update

InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cell interaction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors, or primary cells to mimick structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland.

Current Team (1)

Update

Past Team (1)

Update

Funding Rounds (2) - $3.8M

Update

Investors (2)

Update
  • 2e777d9f70f020260c3b7325004f9c11

    Redalpine Venture Partners

    Redalpine provides venture capital to highly scalable European start-ups. Our mission is to help...
  • Cda26766665b392f5150aac069b820fa

    ZKB Start-up Finance

    Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned...

Offices/Locations (1)

Update
  • Office

    Technoparkstrasse 1

    Zürich, 8005

    CHE